{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T03:54:41Z","timestamp":1781754881527,"version":"3.54.5"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s13555-026-01785-z","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T12:48:14Z","timestamp":1779886094000},"page":"3479-3491","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of Biologic Treatment Duration on Drug-Free Remission in Moderate-to-Severe Psoriasis: A Retrospective Cohort Study"],"prefix":"10.1007","volume":"16","author":[{"given":"Che-Chia","family":"Hsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Huei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1498-1474","authenticated-orcid":false,"given":"Tsen-Fang","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"key":"1785_CR1","doi-asserted-by":"crossref","unstructured":"Ranzinger D, Eyerich K. Disease modification in psoriasis: future prospects for long-term remission. Am J Clin Dermatol. 2025;26(4):477\u201386.","DOI":"10.1007\/s40257-025-00949-5"},{"key":"1785_CR2","doi-asserted-by":"crossref","unstructured":"Armstrong AW, Blauvelt A, Callis Duffin K et al. Psoriasis. Nat Rev Dis Prim. 2025;11(1):45.","DOI":"10.1038\/s41572-025-00630-5"},{"key":"1785_CR3","doi-asserted-by":"crossref","unstructured":"Huang Y-W, Tsai T-F. Remission duration and long-term outcomes in patients with moderate-to-severe psoriasis treated by biologics or tofacitinib in controlled clinical trials: a 15-year single-center experience. Dermatol Ther. 2019;9(3):553\u201369.","DOI":"10.1007\/s13555-019-0310-5"},{"issue":"1","key":"1785_CR4","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jaci.2024.05.008","volume":"154","author":"L Francis","year":"2024","unstructured":"Francis L, Capon F, Smith CH, Haniffa M, Mahil SK. Inflammatory memory in psoriasis: from remission to recurrence. J Allergy Clin Immunol. 2024;154(1):42\u201350.","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"1785_CR5","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1016\/j.jid.2024.09.012","volume":"144","author":"SM Lwin","year":"2024","unstructured":"Lwin SM, Azrielant S, He J, Griffiths CEM. Curing psoriasis. J Invest Dermatol. 2024;144(12):2645\u20139.","journal-title":"J Invest Dermatol"},{"key":"1785_CR6","doi-asserted-by":"crossref","unstructured":"Dong C, Lin L, Du J. Characteristics and sources of tissue-resident memory T\u00a0cells in psoriasis relapse. Curr Res Immunol. 2023;4:100067.","DOI":"10.1016\/j.crimmu.2023.100067"},{"key":"1785_CR7","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1146\/annurev-immunol-032713-120225","volume":"32","author":"MA Lowes","year":"2014","unstructured":"Lowes MA, Su\u00e1rez-Fari\u00f1as M, Krueger JG. Immunology of psoriasis. Annu Rev Immunol. 2014;32:227\u201355.","journal-title":"Annu Rev Immunol"},{"issue":"9","key":"1785_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2023.06.077","volume":"143","author":"A Blauvelt","year":"2023","unstructured":"Blauvelt A, Gudjonsson J, Matheson R, et al. LB1703\u00a0high induction dosing of risankizumab in patients with moderate-to-severe plaque psoriasis: interim results from the phase\u00a02 KNOCKOUT study. J Invest Dermatol. 2023;143(9):B16.","journal-title":"J Invest Dermatol"},{"issue":"10","key":"1785_CR9","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1111\/jdv.19236","volume":"37","author":"K Sch\u00e4kel","year":"2023","unstructured":"Sch\u00e4kel K, Reich K, Asadullah K, et al. Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance (\u2018clinical super response\u2019): week\u00a028 results from the ongoing phase\u00a0IIIb randomized, double-blind, parallel-group, GUIDE study. J Eur Acad Dermatol Venereol. 2023;37(10):2016\u201327.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"1785_CR10","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jamadermatol.2024.2463","volume":"160","author":"K Eyerich","year":"2024","unstructured":"Eyerich K, Asadullah K, Pinter A, et al. Noninferiority of 16-week vs 8-week guselkumab dosing in super responders for maintaining control of psoriasis: the GUIDE randomized clinical trial. JAMA Dermatol. 2024;160(9):953\u201363.","journal-title":"JAMA Dermatol"},{"issue":"10","key":"1785_CR11","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1001\/jamadermatol.2022.2909","volume":"158","author":"ZZN Yiu","year":"2022","unstructured":"Yiu ZZN, Becher G, Kirby B, et al. Drug survival associated with effectiveness and safety of treatment with guselkumab, ixekizumab, secukinumab, ustekinumab, and adalimumab in patients with psoriasis. JAMA Dermatol. 2022;158(10):1131\u201341.","journal-title":"JAMA Dermatol"},{"issue":"10","key":"1785_CR12","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1111\/jdv.20739","volume":"39","author":"L Motedayen Aval","year":"2025","unstructured":"Motedayen Aval L, Yiu ZZN, Alabas OA, et al. Drug survival of IL-23 and IL-17 inhibitors versus other biologics for psoriasis: a British Association of Dermatologists Biologics and Immunomodulators Register cohort study. J Eur Acad Dermatol Venereol. 2025;39(10):1785\u201395.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"1785_CR13","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1111\/jdv.16803","volume":"35","author":"A Al-Hammadi","year":"2021","unstructured":"Al-Hammadi A, Ruszczak Z, Magari\u00f1os G, et al. Intermittent use of biologic agents for the treatment of psoriasis in adults. J Eur Acad Dermatol Venereol. 2021;35(2):360\u20137.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"1785_CR14","first-page":"1106","volume":"23","author":"HY Huang","year":"2025","unstructured":"Huang HY, Tseng IL, Yang CC, et al. Optimizing biologics for chronic plaque psoriasis: insights on non-medical interruptions of IL-17, IL-12\/23, and IL-23 inhibitors. J Dtsch Dermatol Ges. 2025;23(9):1106\u201314.","journal-title":"J Dtsch Dermatol Ges"},{"key":"1785_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.880985","volume":"13","author":"YH Huang","year":"2022","unstructured":"Huang YH, Tang CH, Goh CH, et al. Persistence and adherence to biologics in patients with psoriasis in Taiwan: a new biologics user cohort study. Front Pharmacol. 2022;13:880985.","journal-title":"Front Pharmacol"},{"key":"1785_CR16","doi-asserted-by":"crossref","unstructured":"Hsieh C-Y, Hsu FL-T, Tsai T-F. Comparison of drug-free remission after the end of phase\u00a0III trials of three different anti-IL-23 Inhibitors in psoriasis. Dermatol Ther. 2024;14(9):2607\u201320.","DOI":"10.1007\/s13555-024-01229-6"},{"issue":"6","key":"1785_CR17","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1007\/s40257-024-00887-8","volume":"25","author":"YH Huang","year":"2024","unstructured":"Huang YH, Hung SJ, Lee CN, et al. Predicting the time to relapse following withdrawal from different biologics in patients with psoriasis who responded to therapy: a 12-year multicenter cohort study. Am J Clin Dermatol. 2024;25(6):997\u20131008.","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"1785_CR18","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1111\/bjd.20963","volume":"186","author":"L Puig","year":"2022","unstructured":"Puig L, Costanzo A, Mu\u00f1oz-El\u00edas EJ, et al. The biological basis of disease recurrence in psoriasis: a historical perspective and current models. Br J Dermatol. 2022;186(5):773\u201381.","journal-title":"Br J Dermatol"},{"key":"1785_CR19","doi-asserted-by":"crossref","unstructured":"Kasprowicz-Furma\u0144czyk M, Czerwi\u0144ska J, Placek W, Owczarczyk-Saczonek A. Assessment of the tissue resident memory cells in lesional skin of patients with psoriasis and in healthy skin of healthy volunteers. Int J Environ Res Public Health. 2021;18(21):11251.","DOI":"10.3390\/ijerph182111251"},{"issue":"7","key":"1785_CR20","doi-asserted-by":"publisher","first-page":"3111","DOI":"10.4049\/jimmunol.1302313","volume":"192","author":"S Cheuk","year":"2014","unstructured":"Cheuk S, Wik\u00e9n M, Blomqvist L, et al. Epidermal Th22 and Tc17 cells form a localized disease memory in clinically healed psoriasis. J Immunol. 2014;192(7):3111\u201320.","journal-title":"J Immunol"},{"issue":"11","key":"1785_CR21","doi-asserted-by":"publisher","first-page":"4031","DOI":"10.1172\/JCI93396","volume":"127","author":"TR Matos","year":"2017","unstructured":"Matos TR, O\u2019Malley JT, Lowry EL, et al. Clinically resolved psoriatic lesions contain psoriasis-specific IL-17-producing \u03b1\u03b2 T\u00a0cell clones. J Clin Invest. 2017;127(11):4031\u201341.","journal-title":"J Clin Invest"},{"issue":"2","key":"1785_CR22","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/bjd.17748","volume":"181","author":"S Vo","year":"2019","unstructured":"Vo S, Watanabe R, Koguchi-Yoshioka H, et al. CD8 resident memory T\u00a0cells with interleukin 17A-producing potential are accumulated in disease-na\u00efve nonlesional sites of psoriasis possibly in correlation with disease duration. Br J Dermatol. 2019;181(2):410\u20132.","journal-title":"Br J Dermatol"},{"issue":"4 Suppl 1","key":"1785_CR23","doi-asserted-by":"publisher","first-page":"S171","DOI":"10.1016\/j.jaad.2005.10.029","volume":"54","author":"W Carey","year":"2006","unstructured":"Carey W, Glazer S, Gottlieb AB, et al. Relapse, rebound, and psoriasis adverse events: an advisory group report. J Am Acad Dermatol. 2006;54(4 Suppl 1):S171\u201381.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1785_CR24","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jdermsci.2019.06.002","volume":"95","author":"K Kurihara","year":"2019","unstructured":"Kurihara K, Fujiyama T, Phadungsaksawasdi P, Ito T, Tokura Y. Significance of IL-17A-producing CD8(+)CD103(+) skin resident memory T\u00a0cells in psoriasis lesion and their possible relationship to clinical course. J Dermatol Sci. 2019;95(1):21\u20137.","journal-title":"J Dermatol Sci"},{"key":"1785_CR25","doi-asserted-by":"publisher","unstructured":"Dong C, Sun L, Wang Y et al. CXCR6 sustains TRM-driven psoriasis relapse by CXCL16 chemotaxis and curcumol targeting. J Adv Res. 2025. https:\/\/doi.org\/10.1016\/j.jare.2025.10.066.","DOI":"10.1016\/j.jare.2025.10.066"},{"key":"1785_CR26","doi-asserted-by":"crossref","unstructured":"Zhdanava M, Fitzgerald T, Pilon D et al. Comparative analysis of persistence and remission with guselkumab versus secukinumab and ixekizumab in the United States. J Dermatol Treat. 2024;35(1):2349658.","DOI":"10.1080\/09546634.2024.2349658"},{"issue":"5","key":"1785_CR27","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.immuni.2009.05.001","volume":"30","author":"L Zhou","year":"2009","unstructured":"Zhou L, Chong MM, Littman DR. Plasticity of CD4+ T\u00a0cell lineage differentiation. Immunity. 2009;30(5):646\u201355.","journal-title":"Immunity"},{"issue":"5","key":"1785_CR28","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1016\/j.cell.2019.07.032","volume":"178","author":"MC Amezcua Vesely","year":"2019","unstructured":"Amezcua Vesely MC, Pallis P, Bielecki P, et al. Effector T(H)17 cells give rise to long-lived T(RM) cells that are essential for an immediate response against bacterial infection. Cell. 2019;178(5):1176-88.e15.","journal-title":"Cell"},{"issue":"5","key":"1785_CR29","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.jid.2019.09.027","volume":"140","author":"S Mashiko","year":"2020","unstructured":"Mashiko S, Edelmayer RM, Bi Y, et al. Persistence of inflammatory phenotype in residual psoriatic plaques in patients on effective biologic therapy. J Invest Dermatol. 2020;140(5):1015-25.e4.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"1785_CR30","doi-asserted-by":"publisher","first-page":"209","DOI":"10.5114\/ada.2021.113125","volume":"39","author":"A Owczarczyk-Saczonek","year":"2022","unstructured":"Owczarczyk-Saczonek A, Kasprowicz-Furma\u0144czyk M, Czerwi\u0144ska J, Krajewska-W\u0142odarczyk M, Placek W. The effect of therapy on TRM in psoriatic lesions. Postepy Dermatol Alergol. 2022;39(1):209\u201320.","journal-title":"Postepy Dermatol Alergol"},{"key":"1785_CR31","doi-asserted-by":"crossref","unstructured":"Mehta H, Mashiko S, Angsana J et al. Differential changes in inflammatory mononuclear phagocyte and T-cell profiles within psoriatic skin during treatment with guselkumab vs. secukinumab. J Invest Dermatol. 2021;141(7):1707\u201318.e9.","DOI":"10.1016\/j.jid.2021.01.005"},{"issue":"5","key":"1785_CR32","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1111\/jdv.18846","volume":"37","author":"L Iversen","year":"2023","unstructured":"Iversen L, Conrad C, Eidsmo L, et al. Secukinumab demonstrates superiority over narrow-band ultraviolet B phototherapy in new-onset moderate to severe plaque psoriasis patients: week\u00a052 results from the STEPIn study. J Eur Acad Dermatol Venereol. 2023;37(5):1004\u201316.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"1785_CR33","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/jvc2.63","volume":"1","author":"H Ben Abdallah","year":"2022","unstructured":"Ben Abdallah H, Emmanuel T, Bregnh\u00f8j A, Johansen C, Iversen L. Early intervention and disease memory in psoriasis: a literature review. JEADV Clin Pract. 2022;1(4):307\u201316.","journal-title":"JEADV Clin Pract"},{"issue":"2","key":"1785_CR34","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1111\/jdv.16803","volume":"35","author":"A Al-Hammadi","year":"2021","unstructured":"Al-Hammadi A, Ruszczak Z, Magari\u00f1os G, et al. Intermittent use of biologic agents for the treatment of psoriasis in adults. J Eur Acad Dermatol Venereol. 2021;35(2):360\u20137.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4 Suppl 78","key":"1785_CR35","first-page":"S63","volume":"31","author":"MK Ramirez-Fort","year":"2013","unstructured":"Ramirez-Fort MK, Levin AA, Au SC, Gottlieb AB. Continuous versus intermittent therapy for moderate-to-severe psoriasis. Clin Exp Rheumatol. 2013;31(4 Suppl 78):S63-70.","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"1785_CR36","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s13555-014-0043-4","volume":"4","author":"Y Poulin","year":"2014","unstructured":"Poulin Y, Sheth P, Gu Y, Teixeira HD. Health-related quality of life worsens disproportionately to objective signs of psoriasis after withdrawal of adalimumab therapy. Dermatol Ther. 2014;4(1):33\u201342.","journal-title":"Dermatol Ther"},{"issue":"3","key":"1785_CR37","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1111\/bjd.14622","volume":"175","author":"N Kirsten","year":"2016","unstructured":"Kirsten N, Bulai Livideanu C, Richard MA, et al. Inclusion and exclusion criteria in phase\u00a0III trials with systemic agents in psoriasis: the external validity of drug development. Br J Dermatol. 2016;175(3):636\u20138.","journal-title":"Br J Dermatol"},{"key":"1785_CR38","doi-asserted-by":"crossref","unstructured":"K BG, J FM, Foley P et al. Guselkumab efficacy by psoriasis disease severity and treatment history: VOYAGE 1 and 2 post hoc analyses. J Drugs Dermatol. 2025;24(2):196\u2013202.","DOI":"10.36849\/JDD.8344"},{"issue":"12","key":"1785_CR39","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1111\/jdv.16521","volume":"34","author":"B Strober","year":"2020","unstructured":"Strober B, Menter A, Leonardi C, et al. Efficacy of risankizumab in patients with moderate-to-severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase\u00a0III UltIMMa-1 and UltIMMa-2 studies. J Eur Acad Dermatol Venereol. 2020;34(12):2830\u20138.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"12","key":"1785_CR40","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1111\/exd.14963","volume":"32","author":"CY Hsieh","year":"2023","unstructured":"Hsieh CY, Tseng YH, Tsai TF. Predictors for the effectiveness of 75\u2009mg risankizumab in treating psoriasis-a real-word evidence from a 52-week retrospective study. Exp Dermatol. 2023;32(12):2138\u201348.","journal-title":"Exp Dermatol"},{"issue":"5","key":"1785_CR41","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1007\/s13555-025-01394-2","volume":"15","author":"E Mortato","year":"2025","unstructured":"Mortato E, Talamonti M, Marcelli L, et al. Predictive factors for super responder status and long-term effectiveness of guselkumab in psoriasis: a multicenter retrospective study. Dermatol Ther (Heidelb). 2025;15(5):1239\u201350.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"3","key":"1785_CR42","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s40257-020-00585-1","volume":"22","author":"YW Huang","year":"2021","unstructured":"Huang YW, Tsai TF. HLA-Cw1 and psoriasis. Am J Clin Dermatol. 2021;22(3):339\u201347.","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"1785_CR43","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s13555-022-00883-y","volume":"13","author":"A Asahina","year":"2023","unstructured":"Asahina A, Okubo Y, Morita A, et al. Bimekizumab efficacy and safety in Japanese patients with plaque psoriasis in BE VIVID: a phase\u00a03, ustekinumab and placebo-controlled study. Dermatol Ther (Heidelb). 2023;13(3):751\u201368.","journal-title":"Dermatol Ther (Heidelb)"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01785-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01785-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01785-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T03:25:13Z","timestamp":1781753113000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01785-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,27]]},"references-count":43,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1785"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01785-z","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,27]]},"assertion":[{"value":"25 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Tsen-Fang Tsai has conducted clinical trials or received honoraria for serving as a consultant or speaking fees from Pfizer Limited, Serono International SA (now Merck Serono International SA), UniPharma\/Biogen Idec, Galderma, Celgene, Novartis Pharmaceuticals Corporation, Kyowa Hakko Kirin Taiwan, Boehringer Ingelheim, Bristol Myers Squibb, Janssen-Cilag Pharmaceutica, and AbbVie. Tsen-Fang Tsai is an Editorial Board member of\n                      Dermatology and Therapy\n                      . Tsen-Fang Tsai was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Che-Chia Hsu has nothing to declare. Yu\u2011Huei Huang has conducted clinical trials while serving as a principal investigator for Galderma, Eli Lilly, Novartis Pharmaceuticals Corporation, and Janssen-Cilag Pharmaceutica, has received honoraria for serving as an advisory board member for Pfizer Limited, AbbVie, and Celgene and has received speaking fees from AbbVie, Eli Lilly, and Novartis Pharmaceuticals Corporation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study protocol was reviewed and approved by the local Institutional Review Board of Chang Gung Memorial Hospital, Linkou and Taipei branches (202000677B0); National Taiwan University Hospital (201605118RINB, 201904124RINC).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}